IRIS
RIMASSA, Lorenza
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.062
EU - Europa 1.763
AS - Asia 1.064
AF - Africa 209
SA - Sud America 24
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 11
Totale 10.147
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.976
SG - Singapore 528
FI - Finlandia 444
CN - Cina 355
IE - Irlanda 333
IT - Italia 270
DE - Germania 212
NG - Nigeria 205
FR - Francia 149
NL - Olanda 95
CA - Canada 83
SE - Svezia 72
GB - Regno Unito 63
IN - India 52
TR - Turchia 40
BE - Belgio 32
IL - Israele 28
RU - Federazione Russa 25
HK - Hong Kong 14
JP - Giappone 14
AU - Australia 13
CZ - Repubblica Ceca 12
CL - Cile 11
IR - Iran 10
BR - Brasile 8
EU - Europa 8
UA - Ucraina 8
AT - Austria 7
KR - Corea 7
PL - Polonia 7
BD - Bangladesh 5
CH - Svizzera 5
RO - Romania 5
ES - Italia 4
GR - Grecia 4
PT - Portogallo 4
A2 - ???statistics.table.value.countryCode.A2??? 3
ID - Indonesia 3
ML - Mali 3
VN - Vietnam 3
HR - Croazia 2
MX - Messico 2
NO - Norvegia 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AR - Argentina 1
BG - Bulgaria 1
CO - Colombia 1
HN - Honduras 1
IM - Isola di Man 1
KZ - Kazakistan 1
LT - Lituania 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PK - Pakistan 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 10.147
Salva come PNG Salva come JPEG
Città #
Wilmington 1.287
Chandler 1.285
San Mateo 477
Helsinki 444
Ann Arbor 394
Singapore 343
Dublin 332
Shanghai 277
Lawrence 253
Princeton 252
Boardman 241
Leawood 232
New York 231
Benin City 205
Ashburn 201
Paris 137
Fairfield 108
Woodbridge 108
Milan 103
Amsterdam 90
Toronto 61
London 56
Phoenix 53
Seattle 44
San Diego 42
Kocaeli 39
Santa Clara 39
Abbiategrasso 31
Redwood City 31
Brussels 30
Pune 30
Norwalk 27
Los Angeles 25
Falkenstein 16
Munich 15
Redmond 15
Andover 13
Monmouth Junction 13
Moscow 13
Milwaukee 12
St Louis 12
Brno 10
Hanover 10
Genoa 7
Montreal 7
Falls Church 6
Florence 6
Frankfurt am Main 6
Montréal 6
Tappahannock 6
Winnipeg 6
Buffalo 5
Des Moines 5
Manassas 5
Rome 5
Roubaix 5
Sacramento 5
Shenzhen 5
Umeda 5
Beijing 4
Chengdu 4
Clearwater 4
Houston 4
Jinan 4
Nanjing 4
Porto 4
Raleigh 4
Tai Kok Tsui 4
Tokyo 4
Bamako 3
Cambridge 3
Chicago 3
Freiburg im Breisgau 3
Gurgaon 3
Görwihl 3
Ho Chi Minh City 3
Lausanne 3
São Paulo 3
Verona 3
Warsaw 3
Alexandria 2
Apo 2
Ariano nel Polesine 2
Central District 2
Changzhou 2
Cinisello Balsamo 2
Dhaka 2
Eden Prairie 2
Ferrara 2
Gdynia 2
Guangzhou 2
Gunzenhausen 2
Henderson 2
Jakarta 2
Kemerovo 2
Kolkata 2
La Canada Flintridge 2
Melbourne 2
Modena 2
Monza 2
Totale 7.840
Salva come PNG Salva come JPEG
Nome #
18F-FDG PET and CT scan in the pre-operative evaluation of colorectal liver metastases treated with chemotherapy 74
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 73
An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab 71
18F-FDG pet does not improve contrast enhanced CT scan sensitivity in the evaluation of liver metastases after chemotherapy 68
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 67
Tumor-associated macrophages and response to 5-flourouracil adjuvant therapy in stage III colorectal cancer 66
Metastasis of hepatocellular carcinoma to the heart: A case report and review of the literature 64
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 63
Antiangiogenic drugs currently used for colorectal cancer: What other pathways can we target to prolong responses? 61
Tumor-derived prostaglandin E2 promotes p50 NF-κB-dependent differentiation of monocytic MDSC 61
Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era 61
5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors 60
Can SBRT improve the prognosis of unresectable pancreatic cancer? Clinical results on 106 patients 60
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 59
Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy 59
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 59
Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole 58
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 58
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 58
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression 58
Biomarkers in Hepatocellular Carcinoma-Letter 57
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 57
Tivantinib for hepatocellular carcinoma 57
COVID-19 and liver cancer clinical trials: not everything is lost 56
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 56
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 56
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma 55
Long-term outcomes after pancreatoduodenectomy for ampullary cancer: The influence of the histological subtypes and comparison with the other periampullary neoplasms 55
Cabozantinib for the treatment of hepatocellular carcinoma 54
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 54
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 54
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 53
Chemotherapy with mitomycin c and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin 53
Prognostic value of the immune-related transcriptome in biliary tract cancers 53
FOLFOX/CAPOX in stage II–III colon cancer: efficacy results of the Italian Three Or Six Colon Adjuvant trial (TOSCA) 53
Characterisation of the immune-related transcriptome in resected biliary tract cancers 53
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 53
Clinical implications of immunohistochemical assessment of somatostatin receptors subtype 2 and 5 in the diagnostic and therapeutic management of gastro-entero-pancreatic neuroendocrine tumours 52
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer 52
Case Report of Acute Aortic Dissection during Treatment with Capecitabine for a Late Recurrence of Breast Cancer 51
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 51
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial 51
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 51
Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells 51
High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models 51
Phase III trial comparing 3 to 6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial 51
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 50
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 50
Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial 49
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date 49
Irinotecan and raltitrexed: an active combination in advanced colorectal cancer 49
Adrenal metastases from adenocarcinoma of the esophagogastric junction: adrenalectomy and long-term survival. 49
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 49
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 49
Immunotherapy in hepatobiliary tumors: search for the missing pieces of the puzzle 49
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 49
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 49
Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib 48
Nurses and health care assistants: Evaluation of attitude towards the care of patients who are terminally ill with cancer. 48
Targeted agents for second-line treatment of advanced hepatocellular carcinoma 48
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98 48
Reply to Y. Pointreau et al 48
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up 48
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 48
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 48
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 48
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial. 47
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial 47
Preliminary experience with high-dose cisplatin, reduced glutathione and natural interferon-alpha in dacarbazine-resistant malignant melanoma 47
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 47
F-18-FDG-PET (PET) and contrast-enhanced CT-scan (CT) in the evaluation of liver metastases from colorectal cancer after chemotherapy 47
Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer 47
Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer 47
Effectiveness of precautionary chemotherapy in gastric cancer 46
Medical Oncologists must get more involved in systemic treatment of Hepatocellular Carcinoma 46
Shaping the landscape of immune oncology in hepatocellular carcinoma 46
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 46
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 46
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 46
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer 45
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 45
Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. 45
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma 45
Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients 45
SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. 45
Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane 44
Capecitabine and temozolomide versus FOLFIRI in RAS mutated, MGMT methylated metastatic colorectal cancer 44
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients 44
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition 44
Hepatotoxicity of immune check point inhibitors: Approach and management 44
Metabolic switch in hepatocellular carcinoma patients treated with sorafenib: a proof-of-concept trial 43
The present and the future landscape of treatment of advanced HCC. 43
Caregiver training for a therapeutic alliance in palliative home care. 43
Nicotinamide phosphoribosyltransferase acts as a metabolic gate for mobilization of myeloid-derived suppressor cells 43
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 43
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 43
Combined PD-1/VEGFR blockade: a new era of treatment for hepatocellular cancer 43
Immunotherapy combination strategies in unresectable hepatocellular carcinoma 43
Hepatocellular carcinoma: a global disease in need of individualized treatment strategies 42
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma : a prospective feasibility analysis 42
Totale 5.144
Salva come PNG Salva come JPEG
Categoria #
all - tutte 93.629
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 93.629
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202024 0 0 0 0 0 0 0 0 0 0 3 21
2020/20212.514 21 24 21 12 104 768 355 158 455 314 33 249
2021/20221.504 61 43 20 316 28 33 70 219 136 211 270 97
2022/20233.786 563 174 342 440 302 293 35 310 675 355 257 40
2023/20242.440 161 251 455 89 76 341 161 127 36 53 278 412
2024/2025323 121 62 29 57 54 0 0 0 0 0 0 0
Totale 10.591